Copy For Citation
YAVUZ G., YıLGÖR A., Yavuz I., MILANLıOĞLU A., ÇILINGIR V., ÇAĞAÇ A., ...More
POSTEPY DERMATOLOGII I ALERGOLOGII, vol.36, no.2, pp.211-216, 2019 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
36
Issue:
2
-
Publication Date:
2019
-
Doi Number:
10.5114/ada.2018.74834
-
Journal Name:
POSTEPY DERMATOLOGII I ALERGOLOGII
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Page Numbers:
pp.211-216
-
Keywords:
chronic urticaria, omalizumab, neuropathy, INFLAMMATORY DEMYELINATING POLYNEUROPATHY, SAFETY, TOLERABILITY, NEUROPATHY, URTICARIA, DIAGNOSIS, PATIENT
-
Van Yüzüncü Yıl University Affiliated:
Yes
Abstract
Introduction: Peripheral neuropathy (PN) is a common neurological condition causing symmetrical and diffuse damage in nerves. The etiology of PN includes systemic diseases, toxic exposure, medications, infections, and hereditary diseases. Omalizumab is a humanized monoclonal anti-IgE antibody that exerts its activity by binding to free IgE in circulation.